Numerus using analytics to extract insights from clinical data
SAS® used to help complex statistical analyses now demanded by pharma and healthcare sector
MARLOW, UK – 1 April 2015 - Numerus Ltd, one of Europe’s largest statistical consultancies analysing clinical and healthcare data, has invested in SAS, the global leader in business analytics, to assist with their growing volumes of data and the more sophisticated statistical analyses needed in order to maximise sales of their client’s drugs and medical devices.
The company believes statistics is a crucial strategic component in any clinical development programme, which can deliver substantial savings and increase the chances of a drug’s commercial success. Numerus comprises statisticians and epidemiologists who between them have more than 80 years of combined experience working in the pharmaceutical industry, acquired by working and contracting for companies in Germany, Italy, Switzerland and the UK.
Numerus is investing in further technology from SAS that will allow it to carry out complex statistical analyses on its clients’ data more effectively and more efficiently than before. The implementation of server-based SAS will allow it to grow its business while at the same time significantly reducing the costs per user.
“Providing evidence that a drug is safe and efficacious is often not enough to guarantee sales. The demonstration of cost-effectiveness to payers is another critical hurdle in a drug’s commercial success. An increasing amount of data is now being collected within clinical trials with the specific goal of addressing these cost-effectiveness concerns,” said Dr Jonathan Alsop, Director & Statistician at Numerus. “We foresee that more robust analytical tools and environments (than are currently employed) will be needed in order to convince payers of a drug’s “value for money”. Since Numerus’s inception back in 2006 we have undertaken the vast majority of our analytical processes within a SAS environment. As such, we feel that we are well placed to adapt to the challenges in post-marketing drug approval.”
Andy Cutler, Director of Strategy, SAS UK & Ireland commented: “We’re delighted Numerus selected SAS so it can work more efficiently with its clients’ data and carry out more effective analyses on that data. With our information economy it’s crucial that all organisations are able to maximise the use of their data, in order to provide them the insight they need.”
SAS is the leader in analytics. Through innovative analytics, business intelligence and data management software and services, SAS helps customers at more than 83,000 sites make better decisions faster. Since 1976, SAS has been giving customers around the world THE POWER TO KNOW®.
Numerus is a leading consultancy in providing statistical, epidemiological, and health economic analytical services to the pharmaceutical, medical device and diagnostic industries. With offices in the UK, Germany, and Switzerland, Numerus excels in understanding the nuances of market access within the European reimbursement environment. It has a trusted track record in clinical trial (Phase I-III) biostatistics, a specialised skillset for health technology assessment, and the innovative capabilities to apply statistics to real world data.